The pandemic of H1N1 influenza A (2009) affected more than 0.4 million people in 180 countries around the world. The H and N alphabets refer to H1N1's hemagglutinin and Neuraminidase proteins. Influenza H1N1/09 was first identified in Mexico in March 2009, spreading throughout the United States from there. Avian, swine and human genetic elements were identified in the virus, which is more deadly than influenza H1N1 (Spanish Flu) of 1918.
The vaccination market for disease prevention is projected in the unaffected population in this study. In the early phase of the H1N1 pandemic, drugs to treat patients such as Tamiflu were added. In the later phase, medications will facilitate prevention instead of treating illnesses. Vaccinations will be administered first to priority classes, such as pregnant women, people with chronic illnesses, and children over six months old.
Markets for H1N1 influenza vaccines are expected to bring in $676 million in 2009. More modest growth is expected by the end of 2011 as the largest share of the global population is expected to be vaccinated. The H1N1 vaccine market is listed on the list of intramuscular and intranasal vaccines.
Government intervention and the knowledge of the flu pandemic are influenced by the burgeoning market for H1N1, so market players gain a deeper understanding of the dynamics of the market, technological developments, product pricing, marketing, and regulatory frameworks. GlaxoSmithKline (GSK) and Novartis (SCL), Medimmune, Baxter, Sinovac, and Sanofi Pasteur are the first movers in this group. These companies were authorized by many governments including the United States, the United Kingdom, France, China, Denmark, and Australia. Medimmune, located in the United States, is the only intranasal vaccine producer.